Gilead purchase of novel cancer treatment raises cost issues again
A potential replay of the Sovaldi scandal is further complicated by the way the treatment is administered
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Washington
GILEAD Sciences' acquisition of Kite Pharma has brought it back to a familiar - and contentious - dilemma: How much should a drugmaker charge for a novel drug that has the potential to cure a disease?
Back in 2013, Gilead was battered by public outrage when it priced its hepatitis C treatment Sovaldi at US$84,000, or US$1,000 a pill. The drug, which promised to rid patients of the viral disease in three months, also faced pushback from insurers and government plans that were expected to cover most of the cost.
Share with us your feedback on BT's products and services
TRENDING NOW
Autobahn Rent A Car directors declared bankrupt over S$50 million each owed to DBS
Higher costs, lower returns: Why are Singaporeans still betting on real estate?
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
Loyang Valley sold for S$880 million to SingHaiyi-led consortium
